Franklin Resources Inc. trimmed its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 94.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,817 shares of the company's stock after selling 229,628 shares during the period. Franklin Resources Inc.'s holdings in Harrow were worth $576,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Quest Partners LLC purchased a new position in Harrow during the third quarter valued at $29,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Harrow by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock valued at $57,000 after purchasing an additional 227 shares during the last quarter. nVerses Capital LLC purchased a new position in shares of Harrow during the second quarter valued at about $33,000. Allspring Global Investments Holdings LLC grew its position in shares of Harrow by 2,730.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company's stock valued at $44,000 after purchasing an additional 2,048 shares in the last quarter. Finally, Hills Bank & Trust Co bought a new stake in shares of Harrow in the third quarter worth about $107,000. Institutional investors own 72.76% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the company. B. Riley dropped their price target on Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research note on Wednesday, December 4th. Craig Hallum increased their target price on Harrow from $45.00 to $65.00 and gave the company a "buy" rating in a research report on Friday, October 4th. Finally, Lake Street Capital boosted their price target on shares of Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Friday, October 4th.
Get Our Latest Report on Harrow
Harrow Trading Up 0.5 %
HROW traded up $0.17 on Tuesday, hitting $33.55. The company had a trading volume of 462,922 shares, compared to its average volume of 497,813. The business's fifty day simple moving average is $41.57 and its 200 day simple moving average is $37.57. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 12-month low of $9.13 and a 12-month high of $59.23. The company has a market cap of $1.19 billion, a PE ratio of -35.69 and a beta of 0.69.
Harrow Company Profile
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Featured Articles
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
